How Will the Inclusion of GLP-1s in Medicaid and Medicare Impact Businesses?

Pharmaceutical Executive: How has the rise of GLP-1s impacted businesses outside of pharma?
Jay Bregman: Up until, the rise of these medications has been severely negative for businesses. It’s been an incredible amount of cost and operational complexity. How do we add step therapy, barriers, and prior authorizations to manage the utilization of these drugs. Ultimately, for a lot of businesses in the coming years, the question is how to get off the financial burden of these drugs before it cracks the overstretch pharmacy and medical budgets.

Businesses want to be available to provide for employees and be competitive....